Certara Customers Received 90 Percent of US FDA Novel Drug Approvals for 9th Consecutive Year
April 27, 2023 08:00 ET
|
Certara
PRINCETON, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that 90 percent of new drug approvals by the U.S. Food and Drug...
Certara to Report First Quarter 2023 Financial Results on May 8th, 2023 and Participate in the BofA Securities 2023 Healthcare Conference
April 10, 2023 16:30 ET
|
Certara
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the first quarter of...
A.I. Coming to Certara’s D360 Scientific Informatics Software
March 09, 2023 08:00 ET
|
Certara
PRINCETON, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, is adding deep learning capabilities to D360, a leading scientific informatics...
Certara announces the release of Simcyp™ PBPK Simulator Version 22, expanding ability to simulate untested scenarios for new patient and therapeutic types
March 07, 2023 08:00 ET
|
Certara
PRINCETON, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced the release of Simcyp Simulator Version 22, which includes new...
Certara Reports Fourth Quarter and Full Year 2022 Financial Results
March 01, 2023 16:16 ET
|
Certara
PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the fourth quarter and full year of 2022...
Certara Announces Transition Plan for Chief Financial Officer
March 01, 2023 16:15 ET
|
Certara
PRINCETON, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), announced today that John Gallagher will succeed Andrew Schemick as Chief Financial Officer, effective April 1,...
Certara to Participate in the Barclays Global Healthcare Conference
February 27, 2023 16:30 ET
|
Certara
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the Barclays Global...
Certara to Report Fourth Quarter and Full Year 2022 Financial Results on March 1st, 2023
February 01, 2023 16:30 ET
|
Certara
PRINCETON, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and...
Certara Acquires Vyasa, an Artificial Intelligence Company that Delivers Predictions to Accelerate Scientific Innovation
January 04, 2023 07:31 ET
|
Certara
PRINCETON, N.J., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), today announced it has acquired Vyasa Analytics, LLC. Vyasa provides scalable deep-learning software...
Certara Announces the Completion of Arsenal Capital Partners’ Investment and the Appointment of David Spaight to the Board of Directors
December 08, 2022 16:30 ET
|
Certara
PRINCETON, N.J., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT) today announced that Arsenal Capital Partners (“Arsenal”), a private equity firm specializing in investing in and...